1. Home
  2. VATE vs ACET Comparison

VATE vs ACET Comparison

Compare VATE & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INNOVATE Corp.

VATE

INNOVATE Corp.

SELL

Current Price

$6.54

Market Cap

101.4M

Sector

Industrials

ML Signal

SELL

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$5.25

Market Cap

83.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VATE
ACET
Founded
1994
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
101.4M
83.3M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
VATE
ACET
Price
$6.54
$5.25
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $34.83
AVG Volume (30 Days)
73.7K
★ 288.6K
Earning Date
11-11-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $1,246,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 12.55
N/A
52 Week Low
$3.75
$0.46
52 Week High
$21.30
$9.97

Technical Indicators

Market Signals
Indicator
VATE
ACET
Relative Strength Index (RSI) 33.45 27.24
Support Level $6.48 N/A
Resistance Level $8.23 $8.68
Average True Range (ATR) 0.40 0.61
MACD -0.06 -0.20
Stochastic Oscillator 8.70 1.22

Price Performance

Historical Comparison
VATE
ACET

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: